Skip to main content

Hormone-free solution for vaginal atrophy

Project description

A device for safer vaginal atrophy treatment

Vaginal atrophy is a globally challenging disease for 80 % of menopausal women and breast cancer survivors. It is associated with thinning, inflammation of the vaginal walls due to lower oestrogen levels. Current treatment options: hormone therapy and moisturisers are poorly tolerated due to side effects and safety concerns. The EIC-funded AVeta project has developed a revolutionary device that is hormone-free, natural, safe, affordable and suitable for all women suffering from vaginal atrophy. Treatment provides long-lasting symptom relief and as it is based on the body’s natural healing response, presents with no side effects. It will be clinically prescribed in an outpatient setting and can then be self-administered monthly by patients in the comfort of their homes.


Vaginal Atrophy (VA) is a chronic and progressive condition. VA impacts on the quality of life, relationships, everyday activities and confidence of women sufferers. It is associated with thinning, drying and inflammation of the vaginal tissue. It is experienced by 80% of all women globally and is the most common symptom of the menopause. Over 70% of Breast Cancer Survivors will also suffer from VA due to side effects of chemotherapy and the cancer-blocker drugs they take further exacerbate symptoms of VA. Current treatment options for VA, primarily pharmaceuticals are either ineffective or poorly tolerated. In the EU and US, 3.6m patients of VA reject existing treatments.
AVeta- a medical device delivering the only hormone free, affordable and safe targeted therapy for all women suffering from VA. Solution is based on pathophysiology of wound healing and will be prescribed by a Clinician in an outpatient setting and women will self-administer the therapy monthly at home.


Net EU contribution
€ 2 500 000,00
34 new road
H91 T6TC Galway

See on map

Ireland Northern and Western West
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 314 567,50